Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
November 26 2019 - 8:30AM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced the appointment of James R. Meyers, an
accomplished pharmaceutical executive with three decades of
commercial experience, to the Company's Board of Directors.
"We are pleased that Jim has joined the Sangamo Board of
Directors," said Sandy Macrae, Chief Executive Officer of Sangamo.
"We believe that Jim’s organizational development experience will
provide great benefit to Sangamo as we continue to grow, and that
his commercial, public policy, and pricing and access expertise
will support our later stage programs through to registration and
help get our medicines to patients in need.”
Mr. Meyers has over 30 years of commercial leadership experience
in the biotechnology industry and worked at Gilead from 1996 until
his retirement in February 2018. Most recently, he served as
Gilead’s Executive Vice President of Worldwide Commercial
Operations, where he was responsible for global commercial
activities, including pricing and market access in North America,
Europe, Middle East, Australia and Japan. At Gilead, he
successfully led several important product launches in the HIV and
hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held
positions of increasing responsibility with Zeneca Pharmaceuticals
and Astra USA. He currently serves on the Board of Directors of two
public companies, Arbutus Biopharma Corp. and CytomX Therapeutics,
and remains an active advisor to several major biopharmaceutical
companies. Mr. Meyers holds a B.S. in Economics from Boston
College.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and gene regulation. For more
information about Sangamo, visit www.sangamo.com.
Forward Looking Statements
This press release contains or refers to forward-looking
statements regarding Sangamo's current expectations. These
forward-looking statements include, without limitation, statements
regarding the potential benefits of cell therapy, the Company's
ability to develop and commercialize product candidates to address
genetic diseases with the Company's proprietary technologies and
the timing of commencement or next stages of such programs and the
anticipated benefits therefrom. These statements are not guarantees
of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Actual
results may differ from those projected in forward-looking
statements due to risks and uncertainties that exist in Sangamo's
operations and business environments. These risks and uncertainties
are described more fully in Sangamo's Annual Report on Form 10-K
for the year ended December 31, 2018 as filed with the Securities
and Exchange Commission on March 1, 2019 and Sangamo's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2019 that
it filed on November 6, 2019. Forward-looking statements contained
in this announcement are made as of this date, and Sangamo
undertakes no duty to update such information except as required
under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191126005294/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Media Inquiries – Global Aron
Feingold 510-970-6000, x421 afeingold@sangamo.com
Investor Relations and Media Inquiries –
European Union & United Kingdom Caroline Courme 33 4 97
21 27 27 ccourme@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2023 to Apr 2024